UAE Pharmaceutical Drug Wholesale Guide 2026: MOHAP License + DHA Requirements

Updated August 2026. The UAE pharmaceutical wholesale and drug distribution sector is one of the most tightly regulated business activities in the country, requiring approvals from the federal Ministry of Health and Prevention (MOHAP), plus the emirate-level health authorities — the Dubai Health Authority (DHA) for Dubai operations, the Department of Health Abu Dhabi (DOH) for Abu Dhabi, and the Ministry of Health for the Northern Emirates. Whether you plan to distribute imported branded drugs, wholesale generic medicines, operate a free zone pharmaceutical trading company for GCC re-export, or enter the rapidly growing UAE biosimilars market, this guide covers the drug registration process, wholesale licensing requirements by emirate, GDP compliance obligations, controlled drug rules, and a full AED cost breakdown for 2026.

UAE Pharmaceutical Regulatory Framework: MOHAP, DHA, and DOH

The UAE pharmaceutical sector operates under a three-tier regulatory structure that every drug wholesale company must understand and navigate:

• Federal Level — MOHAP: The Ministry of Health and Prevention has federal authority over drug registration, import regulation, controlled substance licences, and the enforcement of pharmaceutical standards across the UAE. MOHAP’s Drug Control Department maintains the UAE drug register and issues Product Registration Certificates (PRCs) for all drugs authorised for sale in the UAE market.
• Dubai — DHA (Dubai Health Authority): The DHA licenses pharmaceutical wholesalers, retail pharmacies, and pharmaceutical warehouses operating in the Emirate of Dubai, including the Dubai Healthcare City free zone (DHCC). The DHA also regulates the prescription and dispensing of controlled medicines within Dubai’s health facilities.
• Abu Dhabi — DOH (Department of Health Abu Dhabi): The DOH, formerly known as HAAD (Health Authority Abu Dhabi), licenses pharmaceutical wholesale and retail activities in Abu Dhabi Emirate. DOH conducts annual GDP inspections of pharmaceutical warehouses in Abu Dhabi and maintains the Abu Dhabi pharmaceutical supply chain register.
• Northern Emirates: MOHAP’s regional offices in Sharjah, Ajman, RAK, UAQ, and Fujairah issue pharmaceutical wholesale licences in the Northern Emirates, with less complex processes than Dubai and Abu Dhabi but the same underlying drug registration and GDP requirements.

MOHAP Drug Registration: Product Registration Certificate (PRC)

Before any drug can be imported into or distributed within the UAE, it must hold a valid MOHAP Product Registration Certificate (PRC). The drug registration process is one of the most time-consuming and costly steps for pharmaceutical wholesalers entering the UAE market:

• Cost: AED 5,000–20,000 per drug for the registration application fee, depending on the drug category (innovator branded drug, generic, biosimilar, or OTC product) and the dossier pathway used (full CTD dossier, abridged/generic dossier, or MOHAP fast-track mutual recognition with reference regulatory agency).
• Processing time: 12–36 months for a full drug registration. MOHAP’s fast-track pathway for drugs already approved by reference agencies (US FDA, EMA, UK MHRA, Health Canada, TGA Australia, Swiss Medic, or Japan PMDA) can reduce processing to 6–12 months.
• PRC validity: 3–5 years, with renewal required before expiry. Renewal applications must be submitted 9–12 months before expiry to avoid distribution interruption.
• Variation applications: Any change to an already-registered drug — pack size, labelling, manufacturer, or formulation — requires a MOHAP variation application, costing approximately AED 2,000–10,000 per variation.
• Labelling requirements: All drugs distributed in the UAE must be labelled in Arabic and English, with the MOHAP registration number and the local distributor’s name and address printed on the packaging.

Dubai Pharmaceutical Wholesale Licence: DHA + DET Process

Establishing a pharmaceutical wholesale business in Dubai requires dual licensing — a health authority licence from DHA and a trade licence from DET:

1. DET Trade Licence: Apply for a Dubai Economy and Tourism trade licence with the activity “pharmaceutical wholesale” or “drug wholesale trading.” This requires a suitable commercial premises in Dubai, a Memorandum of Association, and the nomination of a licensed pharmacist as the responsible person. Annual cost: AED 10,000–20,000.
2. Responsible Pharmacist: A pharmacist with a valid DHA pharmacist licence must be appointed as the responsible person for the wholesale outlet. The pharmacist’s DHA licence must be current and the pharmacist must be physically present at the licensed premises during operating hours.
3. GDP-Compliant Premises Fit-Out: The wholesale warehouse must meet DHA pharmaceutical storage requirements: segregated areas for quarantine, approved, and rejected stock; temperature-controlled storage as required by the product range; security for controlled medicines; and documented pest control.
4. DHA Pharmaceutical Wholesale Licence Application: Submit the application to DHA’s Health Regulation Sector with supporting documents including the DET trade licence, pharmacist licence, premises photos, storage plan, and standard operating procedures (SOPs) for receipt, storage, distribution, and quality management. DHA licence fee: AED 8,000–15,000/yr.
5. DHA Premises Inspection: DHA inspectors conduct a pre-licensing inspection of the warehouse facility. The premises must fully comply with DHA’s GDP requirements at the time of inspection.

Abu Dhabi Pharmaceutical Wholesale Licence: DOH + ADDED Process

The Abu Dhabi process mirrors Dubai with DOH replacing DHA. Key differences to note:

• DOH (Department of Health Abu Dhabi) issues pharmaceutical wholesale licences in Abu Dhabi through its Pharmaceutical and Supplies department. Annual DOH wholesale licence fee: approximately AED 12,000–25,000/yr.
• The responsible pharmacist must hold a current DOH pharmacist licence (separate from DHA licence — pharmacists must obtain emirate-level licences for each emirate in which they work).
• DOH conducts annual GDP compliance inspection of all licensed pharmaceutical warehouses in Abu Dhabi, with the inspection scope aligned to WHO GDP guidelines.
• Companies also operating in Abu Dhabi free zones (KEZAD, ADAFZ) need the free zone authority’s business licence in addition to the DOH wholesale approval.

Controlled Drugs: MOHAP Special Permits

Narcotics, psychotropics, and other controlled substances are subject to significantly enhanced regulatory controls in the UAE beyond the standard PRC and wholesale licence framework:

• MOHAP Special Permit for each import shipment: A company holding a wholesale licence and drug registration for a controlled substance must still obtain a MOHAP Special Permit for each individual import shipment of that controlled drug. The permit specifies the exact quantity, strength, and dosage form that may be imported, and import cannot commence until the permit is issued.
• Secure storage requirements: Controlled substances must be stored in a dedicated, locked, and alarmed cabinet or vault within the wholesale warehouse, with access restricted to the responsible pharmacist and named deputies.
• Record-keeping: Complete batch-level records of all controlled substance movements — receipts, dispatches, returns, and destructions — must be maintained and made available to MOHAP inspectors on demand. Records must be kept for at least 5 years.
• Quarterly reporting to MOHAP: Wholesale companies holding controlled substance stocks must submit quarterly balance reports to MOHAP detailing opening balances, receipts, distributions, and closing balances.

Free Zone Pharmaceutical Wholesale: JAFZA + MOHAP Dual Licence

Several pharmaceutical companies operate wholesale distribution businesses from UAE free zones — primarily JAFZA and DAFZA — for GCC and regional re-export rather than UAE domestic sale. The regulatory structure for free zone pharmaceutical wholesale differs from mainland wholesale in important ways:

• JAFZA pharmaceutical trading licence + MOHAP approval: A free zone pharmaceutical wholesaler must hold both the JAFZA trading licence and a MOHAP approval for pharmaceutical distribution. The MOHAP approval for free zone operators covers re-export activities and is distinct from the DHA/DOH domestic wholesale licence.
• Cannot sell to UAE mainland: A free zone pharmaceutical wholesale company cannot legally sell or deliver pharmaceuticals directly to UAE mainland hospitals, pharmacies, or distributors without crossing into the UAE customs territory and complying with full mainland DHA/DOH wholesale licensing requirements.
• GCC re-export benefits: Free zone pharmaceutical wholesalers benefit from the 0% UAE customs duty on re-exported goods, making UAE free zones a cost-competitive base for supplying Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman — all of which accept UAE-based pharmaceutical distributors as a supply source.
• Parallel imports prohibited: Parallel importation of branded pharmaceuticals (importing from a third country without the brand manufacturer’s authorisation for UAE distribution) is prohibited under MOHAP regulations. All imported branded drugs must be authorised by the brand owner or their exclusive UAE distributor.

UAE Pharmaceutical Wholesale Cost Breakdown 2026

Cost Item	AED Amount	Notes
Trade licence (pharmaceutical wholesale)	10,000–20,000	DET (Dubai) or ADDED (AD) annual fee
DHA or DOH wholesale licence	8,000–25,000	Annual health authority licence; varies by emirate
MOHAP drug registration per product (PRC)	5,000–20,000	Per drug; multiply by number of SKUs in portfolio
Responsible pharmacist salary (annual)	80,000–150,000	DHA/DOH licensed pharmacist; full-time required
GDP-compliant warehouse fit-out	50,000–200,000	Quarantine area, temp monitoring, controlled cabinet
Warehouse lease (200–500 sqm, year 1)	50,000–120,000	GDP-compliant facility near DXB or Abu Dhabi
Drug import NOC fees (per shipment)	500–2,000	MOHAP import permit per shipment, per product
GDP audit and SOP development	20,000–50,000	Initial GDP compliance consultancy and audit
Year 1 Total (estimated)	300,000–1,000,000	Excluding drug registration costs for large portfolios

UAE Pharmaceutical Market Overview 2026

The UAE pharmaceutical market is valued at approximately AED 15 billion (2025) and has been growing at 6–8% per year, driven by population growth, increasing chronic disease prevalence, expanding health insurance coverage, and government investment in healthcare infrastructure. The dominant local pharmaceutical distributors include Julphar (Gulf Pharmaceutical Industries, RAK-based), Aster DM Healthcare, PureHealth, and a network of speciality distributors covering oncology, rare diseases, and biosimilars. International pharmaceutical companies including Pfizer, Sanofi, Roche, Novartis, and Abbott maintain UAE subsidiary offices and distribution operations to serve the GCC market.

Frequently Asked Questions

How long does MOHAP drug registration take and can I expedite it?

Standard MOHAP drug registration for a new product takes 12–36 months depending on the drug category, dossier completeness, and MOHAP’s current review backlog. MOHAP offers a fast-track pathway for drugs that already hold approval from one or more reference regulatory agencies (US FDA, EMA, UK MHRA, Health Canada, TGA Australia, Swiss Medic, or Japan PMDA) — this pathway can reduce registration time to 6–12 months. Submitting a complete, well-prepared CTD dossier with no deficiencies, using an experienced local regulatory affairs consultant, and responding promptly to MOHAP’s queries are the primary ways to avoid delays. There is no formal fee-based accelerated review programme comparable to FDA Breakthrough Therapy or EMA PRIME in the UAE at present.

Can a company with a JAFZA pharmaceutical licence sell to UAE mainland hospitals?

No. A JAFZA pharmaceutical trading licence (free zone licence) authorises drug wholesale and re-export activities within the free zone and to international customers — it does not authorise direct sale or delivery of pharmaceuticals to UAE mainland hospitals, clinics, or pharmacies. To supply UAE mainland health facilities, a company must either: (a) establish a separate mainland-licenced pharmaceutical wholesale entity with DHA (Dubai) or DOH (Abu Dhabi) wholesale approval; or (b) appoint an existing mainland-licensed pharmaceutical distributor to purchase goods from the free zone entity and distribute them on the mainland. Many pharmaceutical companies use a combination — free zone entity for import and GCC re-export, mainland entity for local UAE distribution.

Are parallel imports of branded pharmaceuticals permitted in the UAE?

No. Parallel imports of branded pharmaceuticals — importing from a third country without the express authorisation of the brand manufacturer or their UAE-designated exclusive distributor — are prohibited under MOHAP pharmaceutical regulations. All branded drugs sold in the UAE must be supplied through the authorised UAE distributor named in the MOHAP product registration. MOHAP actively polices parallel imports, and customs authorities are alerted to suspect consignments. Companies found importing parallel pharmaceuticals face licence suspension, product seizure, and fines. Generic drugs and biosimilars registered under their own separate PRCs (not relying on a brand’s registration) can be imported by any licenced wholesale company holding the relevant product’s PRC.

What is the MOHAP import NOC and how often is it required?

A MOHAP import NOC (No Objection Certificate) or drug import permit is required for each individual import shipment of a registered pharmaceutical product entering the UAE. Even if a company holds the MOHAP PRC for a drug, it must apply for a shipment-specific import permit before each consignment clears UAE customs. The permit specifies the exact product, quantity, batch numbers, and expiry dates of the shipment. For standard drugs, the NOC is typically issued within 3–7 working days via MOHAP’s online portal. For controlled drugs, the MOHAP Special Permit process takes longer (2–4 weeks) and requires additional documentation from the exporting country’s regulatory authority.

Does a pharmaceutical wholesale company need a pharmacist if it only handles OTC products?

Yes. Under both DHA and DOH regulations, a licensed UAE pharmacist must be the named responsible person for any pharmaceutical wholesale outlet — regardless of whether the product range is limited to over-the-counter (OTC) products or includes prescription medicines. The pharmacist must hold a current DHA or DOH pharmacist licence (as applicable) and must be physically present at the wholesale premises during operating hours. This requirement reflects the UAE’s approach of maintaining pharmacist oversight across the entire pharmaceutical supply chain, from import to dispensing. Some Northern Emirates have slightly different arrangements for pure OTC distributors — consult MOHAP’s regional office for emirate-specific guidance.